

Monica Valeria Estrada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2321050/publications.pdf>

Version: 2024-02-01

27
papers

5,585
citations

236925

25
h-index

377865

34
g-index

34
all docs

34
docs citations

34
times ranked

10798
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117065119.	7.1	26
2	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Medicine, 2019, 11, 34.	8.2	732
3	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease, 2018, 9, 21.	6.3	16
4	USP11 Enhances TGF β -Induced Epithelial \rightarrow Mesenchymal Plasticity and Human Breast Cancer Metastasis. Molecular Cancer Research, 2018, 16, 1172-1184.	3.4	41
5	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26
6	Post \rightarrow radiation morphea of the breast: a case report and review of the literature. Histopathology, 2018, 72, 342-350.	2.9	18
7	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	5.0	128
8	A Phase Ib Study of Alpelisib (BYL719), a PI3K β -Specific Inhibitor, with Letrozole in ER+/HER2 \rightarrow Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
9	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	7.0	104
10	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
11	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 2017, 77, 3280-3292.	0.9	76
12	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine, 2017, 9, .	12.4	89
13	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
14	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research, 2017, 15, 259-268.	3.4	40
15	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
16	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Journal of the National Cancer Institute, 2017, 109, .	6.3	29
17	Genomic profiling of ER \rightarrow breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
18	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non \rightarrow Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	4.3	530

#	ARTICLE	IF	CITATIONS
19	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
20	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. <i>PLoS ONE</i> , 2016, 11, e0157368.	2.5	975
21	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. <i>Cancer Research</i> , 2016, 76, 4752-4764.	0.9	71
22	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	12.8	412
23	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	12.4	105
24	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	7.0	428
25	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. <i>Cancer Research</i> , 2015, 75, 405-414.	0.9	53
26	LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 5490-5502.	8.2	34
27	Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2. <i>Clinical Cancer Research</i> , 2013, 19, 5390-5401.	7.0	67